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1  |  INTRODUC TION
Severe	acute	respiratory	syndrome	coronavirus-	2	(SARS-	CoV-	2),	the	
causative	agent	for	coronavirus	disease-	2019	(COVID-	19),	was	first	





number	 of	COVID-	19	 cases	 fell	 during	May/June,	 initial	 lockdown	
measures	were	eased.	However,	new	restrictions	are	being	increas-
ingly	implemented	at	the	time	of	writing.
For	 transplant	 programs,	 hospital	 resource	 requirements,	 the	
availability	 and	 safety	 of	 deceased	organ	 donors	 and	 the	 safety	 of	
transplant	candidates	and	recipients,	have	forced	difficult	decisions	



















2.1  |  Study population
All	 adult	 and	 paediatric	 lung	 transplant	 centers	 in	 the	 UK	 were	
included	 in	 the	 study.	 Analysis	 included	 all	 adult	 (aged	 16	 years	
and	older)	 and	pediatric	 organ	donors,	 lung	 transplant	waiting	 list	
candidates,	 and	 lung	 transplant	 recipients.	 Heart-	lung	 candidates	
and	recipients	were	not	included	in	the	analysis.
2.2  |  Study design












transplant	 activity,	 early	 (30-	day)	 mortality	 for	 recipients	 trans-
planted	 during	 the	 pandemic	 period,	 lung	 transplant	 candidate	
listing,	 and	waiting	 list	 activity,	 including	mortality	 and	COVID-	19	
infection	in	lung	transplant	recipients.	Prospective	reporting	to	the	
UKTR,	of	 all	 transplant	 recipients,	or	patients	on	 the	organ	 trans-





2.3  |  Survey design and conduct
The	 survey	 was	 developed	 using	 an	 iterative	 process	 based	 on	
literature	 review	 and	 UK	 organ	 donation	 and	 transplantation	
guidance	issued	by	NHSBT	and	the	British	Transplant	Society,	to	
identify	 changes	 in	 lung	 transplantation	 clinical	 practice,	 includ-
ing	candidate	assessment,	recipient	management,	organ	donation,	
and	 activity,	 perceptions	 of	 the	 prevalence	 of	 COVID-	19	 locally	
and	 the	 impact	 on	 the	 transplant	 workforce	 and	 hospital	 re-
source.	The	final	survey	was	approved	by	members	of	the	NHSBT	
Cardiothoracic	Advisory	Group	Clinical	Audit	Group	(CTAG	CAG).	
The	 NHS	 England	 coronavirus	 specialty	 guide	 cardiothoracic	
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escalation	framework10	was	used	to	define	phases	in	response	to	
the pandemic.
The	 survey	 was	 conducted	 between	 May	 15	 and	 June	 18,	
2020.	 At	 each	 center,	 a	 cardiothoracic	 transplant	 clinical	 lead	
and	 transplant	 coordinator	were	 identified	 to	 complete	 the	 sur-
vey.	Participants	were	emailed	a	copy	of	the	survey.	 Information	
required	to	complete	the	survey	was	gathered	by	the	nominated	
persons,	 from	members	of	 the	wider	team.	Additional	 telephone	
interview	follow-	up	was	performed	between	June	20	and	July	13,	
2020,	where	 further	 information	was	required,	or	 to	clarify	spe-
cific	survey	responses.
2.4  |  Statistical analysis
Categorical	variables	are	expressed	as	absolute	numbers	and	their	
relative	 frequencies,	 with	 percentage	 change	 compared	with	 pre-
vious	year,	where	appropriate.	Continuous	variables	are	expressed	
as	 mean	 ±	 standard	 deviation	 (SD)	 if	 normally	 distributed,	 or	 as	
median	 and	 inter-	quartile	 range	 (IQR)	 if	 non-	normally	 distributed.	







2.5  |  Ethical approval
Data	 analyses	 were	 performed	 by	 NHSBT,	 who	 maintain	 the	 UK	













































Early	March Not applicable Not applicable Not applicable Not applicable Not applicable
Center C
ECMO	center




Early	March Mid-	March Late	March Not applicable Early	May Late	May
Center	E
ECMO	center
Early	March Late	March EarlyApril Mid-	April Mid-	May Late	May
Center	F February Early	March Mid-	March Not applicable Mid-	May Late	May











In	 the	 survey	 responses,	 all	 centers	 described	 formal	 or	 infor-
mal,	 center-	level	changes	 to	 lung	donor	acceptance	criteria	during	
the	 pandemic.	 Changes	 described	 included	 consideration	 of	 ideal 
donors	only,	lower	age	limits	for	potential	donors	and	increased	cau-
tion	when	considering	travel	and	ischemic	times.
3.2  |  Lung transplant activity and post- 
transplant outcomes
All	centers	 reported	a	period	of	 restricting	 lung	transplantation	to	
urgent	or	super-	urgent,	inpatient	candidates	only,	at	the	start	of	the	












in	 donors	 offered	 for	 lung	 transplantation	 and	 lung	 transplant	 ac-
tivity	are	shown	in	Figure	1.	The	mean	number	of	transplants	per-
formed,	per	month,	 in	2019	was	15,	 compared	with	9	per	month,	












92%	 (11/12	 recipients).	 Recipient	 characteristics,	 compared	 with	
those	from	the	same	period	of	2019,	are	shown	in	Table	4.











3.4  |  Recipient management
All	 centers	 reported	 that	 active	 efforts	 had	been	made	 to	 reduce	
hospital	 attendance	 for	 lung	 transplant	 recipients.	 At	 the	 time	 of	
the	 survey,	 in	 all	 cases,	 these	 changes	were	 planned	 to	 continue.	
Face-	to-	face	 follow-	up	has	been	 reduced	 to	only	 those	within	 the	
first	6	months	of	transplant	in	one	center,	and	those	within	the	first	
12-	months	of	transplant	in	the	remaining	5	centers.	All	centers	have	









well.	Where	 COVID-	19	 infection	 was	 suspected	 or	 confirmed,	 all	
centers	reported	cessation,	or	dose	reduction,	of	Calcineurin	inhibi-
tors	on	an	individual	patient	basis.







lung (s) were 
offered 
March 1 























March 46 (60) 12 (28) 58 (88) −34%
April 22 (48) 3 (22) 25 (70) −64%
May 30 (55) 10 (25) 40 (80) −50%
Total 98 (163) 25 (75) 123 238 −48%
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3.5  |  COVID- 19 in lung transplant recipients
Twenty-	six	lung	transplant	recipients	with	confirmed	COVID-	19	in-
fection	were	reported,	during	the	study	period.	Median	(IQR)	age	of	
COVID-	19-	positive	 recipients	 is	58	years	 (40–	65).	Mean	 (SD)	 time	
since	transplant	5.3	years	(5.1).	Three	of	the	COVID-	19-	positive	re-
cipients	 had	 been	 transplanted	 during	 the	 early	 pandemic	 period,	
March	to	May	2020.	All	were	listed	prior	to	March	2020,	and	their	
indication	for	transplant	was	not	related	to	COVID-	19	infection.	One	
recipient	 tested	 positive	 after	 hospital	 discharge,	 following	 recov-
ery	from	their	transplant.	One	patient	had	a	positive	result	reported	
pre-	transplantation,	with	a	subsequent	negative	result,	underwent	
lung	 transplant	 and	 remained	 asymptomatic	 for	 COVID-	19.	 One	
patient	had	a	positive	pre-	operative	swab	test,	the	result	of	which	
was	not	 immediately	available	at	 the	 time	of	 implantation.	Due	 to	






age	of	4	 lung	 transplants	was	performed	each	month	of	 the	early	
pandemic	period,	 compared	with	12.5	 transplants	per	month	dur-




The	 number	 of	 deceased	 donors	 from	 whom	 the	 lungs	 were	
offered	 for	 transplantation	 fell	 by	 48%,	 mirroring	 the	 published	
TA B L E  3 Characteristics	of	donors	(*who	donated	at	least	1	solid	organ)	where	the	lung(s)	were	offered	from	March	1	to	May	31,	2020,	
and	March	1	to	May	31,	2019
Number of deceased donors * where the 
lung (s) was offered for donation March 1 to 
May 31, 2020 N = 123
Number of deceased donors * where the 
lung (s) was offered for donation March 1 to 














Donor	age	(years),median	(IQR) 43	(30-	56) 52	(42-	61) <.0001
Donor	sex	male,	n	(%) 73	(59%) 131	(55%) .5026
Donor	BMI	(kg/m2),	median	(IQR) 25	(22.3-	28.3) 26.2	(22.9-	29.9) .1237
Cause	of	death,	n	(%)









No 41 34% 112 47% .0180
Yes 81 66% 125 53%
Unknown 1 1
Donor	past	diabetes,	n	(%)
No 116 96% 216 91% .1569
Yes 5 4% 21 9%
Unknown 2 1
Donor	past	cardiothoracic	disease,	n	(%)
No 108 88% 204 86% >.999
Yes 15 12% 28 12%
Unknown 0 6
Utilization	rate 10% 22%


























Lung donor offered Lung transplanted
TA B L E  4 Recipient	characteristics	for	lung	transplants	performed	from	March	1	to	May	31,	2020,	compared	with	March	1	to	May	31,	
2019
Lung(s) transplant recipients March 1 to May 
31, 2020 N= 12
Lung(s) transplant recipients March 1 to 







Donor	age	(years),	median	(IQR) 33	(23-	50) 53	(42-	61) .0042
Pediatric	donor,	n	(%) 1	(8%) 1	(2%) .3375
Recipient	age	(years),	Median	(IQR) 50.5	(32-	61) 53	(37-	59) .8923
Pediatric	recipient,	n	(%) 0 3	(5%) >.999
Donor	sex	male,	n	(%) 5	(42%) 20	(38%) >.999
Donor	BMI	(kg/m2),	median	(IQR) 24	(22.3-	28) 25	(21-	29) .7831
Donor	cause	of	death,	n	(%)
Intracranial 11	(92%) 51	(96%) .4637
Trauma 0 0
Other 1	(8%) 2	(4%)
Donor	past	smoker,	n	(%) 6	(50%) 18	(35%) .3414






Double/bilateral 12	(100%) 48	(91%) .5746
Status	n,	(%)
Routine 10	(83%) 46	(87%)
Urgent 2	(17%) 5	(9%) .7412
Super-	urgent 0 2	(4%)
30-	day	survival	%	(95%	CI) 91.7	(53.9-	98.8) 96.2	(85.7-	99) .5176
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offered.	 In	UK	 lung	transplant	practice	over	the	 last	5	years,	DCD	



















and	 testing,	 candidate	 testing,	 and	 donor	management	 practice.12 
Potential	donors	are	epidemiological	screened	for	history	of	symp-
toms,	history	of	positive	 testing	or	 contact	with	 a	positive	 and/or	





period,	 transplant	 and	 organ	 implantation	may	 proceed	 prior	 to	 a	
result	being	available,	depending	on	clinical	urgency	and	logistics.	As	
the	pandemic	has	progressed,	the	availability	and	rapidity	of	testing,	

















organ	 donation,	with	 liaison	with	microbiology/virology	 clinicians.	
As	 the	 pandemic	 continues,	 this	 guidance	 we	 undergo	 continued	
review.
The	 published	 experience	 of	 thoracic	 transplant	 programs	
around	the	world	during	this	time,	describe	the	greatest	decreases	
in	lung	transplant	activity	focused	in	those	areas	hardest	hit	by	the	
virus.14	 There	 was	 similar	 heterogenous	 geographical	 spread	 of	
COVID-	19	 infection	 across	 the	UK,	 during	 this	 early	 phase	of	 the	
pandemic,	 with	 varying	 degrees	 of	 viral	 prevalence	 and	 subse-
quent	 hospital	 and	 intensive	 care	 unit	 (ICU)	 resource	 impact.	 It	 is	
clear,	however,	from	individual	center	responses	to	the	survey,	that	
transplant	 activity	 was	 not	 solely	 affected	 by	 local	 prevalence	 of	
COVID-	19	infection.
Here,	the	primary	driver	for	the	decrease	in	lung	transplant	ac-




reduction	 in	 utilization	has	 occurred	 in	 response	 to	 local,	 hospital	
level	 decision-	making,	 initially	 limiting	 solid	 organ	 transplantation,	
during	 this	 period,	 to	urgent,	 inpatient	 candidates,	 only.	Concerns	
about	a	surge	 in	COVID-	19	cases,	and	the	subsequent	demand	on	
intensive	 care	 unit	 capacity,	 lead	 to	 restriction	 of	 access	 for	 non-	





when	 considering	 those	 candidates	who	were	non-	urgent.	Urgent	





















March 17 (26) 1 (0) 0 (0)
April 9 (29) 0 (4) 0 (1)
May 3 (17) 1 (3) 0 (1)
June 4 (21) 0 (4) 0 (3)
Total 33 (93) 2 (11) 0 (5) 35	(109) -	68%
TA B L E  5 The	number	of	new	
registrations,	by	urgency,	per	month,	to	
the	lung	transplant	waiting	list
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patients,	and	as	such	perhaps	require	separate	classification	in	con-
sideration	of	adoption	of	similar	practice	guidance	in	future.
In	 lung	 transplant	 practice,	 changes	 to	 clinical	 practice	 were	
driven	 by	 appropriate	 concerns	 regarding	 the	 safety	 of	 donors,	
hospital-	acquired	 infection	 in	 recipients	 and	 the	 resource	 capacity	
required	to	meet	the	needs	of	COVID-	19	patients.	It	is	evident	from	
the	survey	responses,	that	in	addition	to	national	guidance,	changes	
to	 donor	 consideration	 and	 acceptance	 criteria	 were	 made,	 at	 a	
center-	level,	 variably	 influenced	by	 the	above	concerns.	Allocation	
for	non-	urgent	recipients	 in	the	UK	is	center-	based,	 in	response	to	
group	offering.	Again,	during	the	early	pandemic	period,	lung	trans-
plant	 teams	 exhibited,	 understandable,	 increased	 caution	 when	
considering	the	risks	to	their	candidates	and	this	influenced	decision-	
making	behavior.	These	center-	led	changes	to	practice	evolved	over	
time	during	 the	 early	 pandemic	 period	 and	non-	urgent	 candidates	
were	 increasingly	considered.	Over	the	early	pandemic	period	as	a	
whole,	 only	2	 recipients	 transplanted	 at	 this	 time	 listed	 as	urgent,	
the	remaining	10	were	non-	urgent	patients.	Activity	data	from	June	





Where	 lung	 transplant	 activity	 has	 continued	 during	 this	 early	
pandemic	period,	 it	 has	been	 facilitated	by	 the	designation	of	one	
center	 as	 a	 “COVID-	light”	 hospital.	 Information	 provided	 by	 the	
Royal	 College	 of	 Surgeons	 of	 England15	 describes	 COVID-	light	 as	
physical	 separation	 of	 COVID-	19-	positive	 and	 COVID-	19-	negative	
patients	within	designated	areas	of	NHS	hospitals	or	 for	 an	entire	
hospital,	functioning	as	an	NHS	network	hub.	These	areas	can	only	
be	 maintained	 with	 implementation	 of	 care	 pathways	 to	 include	




high	 local	 prevalence	 of	 the	 virus	 in	 relation	 to	 this	 center,	 it	was	
able	 to	 continue	 activity	 and	was	 responsible	 for	58%	of	 the	 lung	
transplants	performed,	during	this	time.	 In	contrast,	designation	of	
some	UK	 lung	transplant	centers	 for	 the	provision	of	veno-	venous	




















are	 also	 at	 increased	 risk	of	 acquiring	COVID-	19,	 and	developing	
the	more	severe,	 life-	threatening	form	of	the	disease.	Analysis	of	




plantation	 during	 a	 viral	 pandemic.	Our	 analysis	 identified	 just	 2	
lung	 waiting	 list	 candidates	 with	 confirmed	 COVID-	19	 infection	
during	the	study	period.	The	accuracy	of	COVID-	19	data	is	depen-
dent	 on	 additional	 reporting	of	 results,	 by	 centers,	 to	UKTR	 and	










The	SARS-	CoV-	2	pandemic	has	 resulted	 in	changes	 to	clinical	
practice	 in	 lung	 transplantation	 in	 the	 UK.	 UK	 lung	 transplant,	
and	 individual	 centers,	 have	 successfully	 adapted	 their	 programs	
to	 overcome	 the	 challenges	 of	 staff	 sickness,	 redeployment	 and	
potential	 resource	 limitations	 associated	 with	 the	 SARS-	CoV-	2	













March 352 (337) 9 (2) 3 (8) 7 (13)
April 350 (332) 8 (5) 1 (3) 1 (21)
May 341 (325) 4 (5) 1 (3) 4 (19)
Total 21 (12) 5 (14) 12 (53)














opment	and	quality	 improvement	 in	practice.	Funding	for	 this	 in-
novation,	and	ensuring	equity	of	access	for	the	patient	population,	




Hopes	 that	 the	 pandemic	would	 peak	 and	 resolve	 after	 spring	
2020	 in	 the	UK	are	 fading.	 It	 is	 increasingly	 evident	 that	 this	 pan-
demic	will	move	in	waves	and,	at	the	time	of	writing,	the	volume	of	




resource	will	be	 less	acutely	 felt	 than	earlier	 in	 the	year.	However,	
the	 risks	 specific	 to	 lung	 transplant	 candidates,	 recipients,	 and	 the	






vaccination	program	 for	 transplant	 candidates	would	be	 invaluable	
in	reducing	risk	and	allowing	patients	to	remain	active	on	the	wait-
ing	 list.	Protection	of	transplant	resource	capacity	 is	required,	with	
attempts to maintain COVID- light	 hospitals	 in	 line	with	 recommen-





considered,	maintaining	 access	 for	 all.	 Reviewing	 our	 practice,	 and	
sharing	experience	from	this	early	phase	of	the	pandemic,	is	funda-
mental	in	ensuring	the	safe	continuation	of	lung	transplantation.
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